JP2007508040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508040A5 JP2007508040A5 JP2006530148A JP2006530148A JP2007508040A5 JP 2007508040 A5 JP2007508040 A5 JP 2007508040A5 JP 2006530148 A JP2006530148 A JP 2006530148A JP 2006530148 A JP2006530148 A JP 2006530148A JP 2007508040 A5 JP2007508040 A5 JP 2007508040A5
- Authority
- JP
- Japan
- Prior art keywords
- ray
- energy
- intensity
- detector
- pixel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002872 contrast media Substances 0.000 claims description 44
- 238000010521 absorption reaction Methods 0.000 claims description 35
- 238000003384 imaging method Methods 0.000 claims description 24
- 229910052740 iodine Inorganic materials 0.000 claims description 21
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 20
- 239000011630 iodine Substances 0.000 claims description 20
- 238000001228 spectrum Methods 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 10
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 8
- 229910052797 bismuth Inorganic materials 0.000 claims description 8
- 230000002596 correlated Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 238000005755 formation reaction Methods 0.000 claims description 6
- 229910052788 barium Inorganic materials 0.000 claims description 5
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004364 calculation method Methods 0.000 claims description 2
- 230000001678 irradiating Effects 0.000 claims description 2
- 229910052747 lanthanoid Inorganic materials 0.000 claims 3
- 150000002602 lanthanoids Chemical class 0.000 claims 3
- IOWXSDIECPGQBU-UHFFFAOYSA-M [I-].[Ba+] Chemical compound [I-].[Ba+] IOWXSDIECPGQBU-UHFFFAOYSA-M 0.000 claims 1
- 238000005259 measurement Methods 0.000 description 17
- 229910052688 Gadolinium Inorganic materials 0.000 description 15
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 14
- 238000010586 diagram Methods 0.000 description 9
- 239000004065 semiconductor Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 125000002346 iodo group Chemical group I* 0.000 description 6
- 210000000481 Breast Anatomy 0.000 description 5
- 238000002083 X-ray spectrum Methods 0.000 description 5
- -1 ioprol Chemical compound 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002601 radiography Methods 0.000 description 5
- 241001479434 Agfa Species 0.000 description 4
- YVPYQUNUQOZFHG-UHFFFAOYSA-N Diatrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 4
- DGAIEPBNLOQYER-UHFFFAOYSA-N Iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 229910052746 lanthanum Inorganic materials 0.000 description 4
- 230000003902 lesions Effects 0.000 description 4
- 238000009607 mammography Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000003595 spectral Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- XUHXFSYUBXNTHU-UHFFFAOYSA-N 2,4,6-triiodo-5-[methyl-[3-oxo-3-[2,4,6-triiodo-N-methyl-3,5-bis(1,3,4-trihydroxybutan-2-ylcarbamoyl)anilino]propanoyl]amino]-1-N,3-N-bis(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N Iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 3
- 229960003182 Iotrolan Drugs 0.000 description 3
- 210000002356 Skeleton Anatomy 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229960001025 iohexol Drugs 0.000 description 3
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum Chemical group [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 229910052692 Dysprosium Inorganic materials 0.000 description 2
- MXZROTBGJUUXID-UHFFFAOYSA-K Gadobenic acid Chemical compound [H+].[H+].[Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-K 0.000 description 2
- 229960004647 Iopamidol Drugs 0.000 description 2
- IUNJANQVIJDFTQ-UHFFFAOYSA-N Iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 2
- 229960002603 Iopromide Drugs 0.000 description 2
- 229910021417 amorphous silicon Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- KQVYJTGXCBDDLP-UHFFFAOYSA-N gadodiamide hydrate Chemical compound O.C1C[N]2(CC(=O)[O-]3)CC[N]4(CC(NC)=O5)CC(=O)[O-][Gd+3]332425[O-]C(=O)C[N]31CC(NC)=O2 KQVYJTGXCBDDLP-UHFFFAOYSA-N 0.000 description 2
- 150000002251 gadolinium compounds Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 2
- 229960000824 iopentol Drugs 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000005469 synchrotron radiation Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YMFIJXDFAPHJIN-UHFFFAOYSA-N 2-[2-(3-acetamido-2,4,6-triiodophenoxy)ethoxymethyl]butanoic acid Chemical compound CCC(C(O)=O)COCCOC1=C(I)C=C(I)C(NC(C)=O)=C1I YMFIJXDFAPHJIN-UHFFFAOYSA-N 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 230000005461 Bremsstrahlung Effects 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K Gadobutrol Chemical class [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 description 1
- 229960005063 Gadodiamide Drugs 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K Gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- YLPBXIKWXNRACS-UHFFFAOYSA-N Iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 description 1
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- 229960000929 Iotalamic acid Drugs 0.000 description 1
- 229940029378 Iothalamate Drugs 0.000 description 1
- JXMIBUGMYLQZGO-UHFFFAOYSA-N Iotroxic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I JXMIBUGMYLQZGO-UHFFFAOYSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- OLAOYPRJVHUHCF-UHFFFAOYSA-N Ioxitalamic acid Chemical compound CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I OLAOYPRJVHUHCF-UHFFFAOYSA-N 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 229940083599 Sodium Iodide Drugs 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000010406 cathode material Substances 0.000 description 1
- 238000002585 cerebral angiography Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium Chemical group [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-J gadoterate Chemical compound C1C[N+]2(CC([O-])=O)CC[N+]3(CC([O-])=O)CC[N+]4(CC(=O)[O-])[Gd-]32[N+]1(CC([O-])=O)CC4 GFSTXYOTEVLASN-UHFFFAOYSA-J 0.000 description 1
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 1
- UBMJXBCCRVPFQW-UHFFFAOYSA-N gadoteridol Chemical compound C1C[N]2(CC([O-]3)=O)CC[N]4(CC([O-]5)=O)[Gd+3]22635([O-]C(C3)=O)O([H])C(C)C[N]12CC[N]63CC4 UBMJXBCCRVPFQW-UHFFFAOYSA-N 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960004108 iobitridol Drugs 0.000 description 1
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical group [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 description 1
- 229950011575 iopronic acid Drugs 0.000 description 1
- 229960000506 iotroxic acid Drugs 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 229960003781 ioxitalamic acid Drugs 0.000 description 1
- 150000002603 lanthanum Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 238000002587 lymphangiography Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2003147961 DE10347961A1 (de) | 2003-10-10 | 2003-10-10 | Röntgenanordnung und Röntgenkontrastverfahren zur Bildgebung an einem mindestens ein röntgenkontrastgebendes Element enthaltenden Untersuchungsobjekt sowie Verwendung der Röntgenanordnung |
| PCT/EP2004/011436 WO2005034755A1 (de) | 2003-10-10 | 2004-10-07 | Röntgenanordnung und röntgenkontrastverfahren zur bildgebung an einem mindestens ein röntgenkontrastgebendes element enthaltenden untersuchungsobjekt sowie verwendung der röntgenanordnung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508040A JP2007508040A (ja) | 2007-04-05 |
| JP2007508040A5 true JP2007508040A5 (ru) | 2010-07-29 |
Family
ID=34428426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530148A Pending JP2007508040A (ja) | 2003-10-10 | 2004-10-07 | Ｘ線不透過性要素を含む少なくとも１つの被検体での画像形成用のｘ線装置及びｘ線コントラスト方法並びにｘ線装置の使用 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1673012A1 (ru) |
| JP (1) | JP2007508040A (ru) |
| DE (1) | DE10347961A1 (ru) |
| WO (1) | WO2005034755A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005026940A1 (de) * | 2005-06-06 | 2006-12-14 | Schering Ag | Röntgenanordnung zur Bilddarstellung eines Untersuchungsobjektes und Verwendung der Röntgenanordnung |
| DE102005037367B3 (de) * | 2005-08-08 | 2007-04-05 | Siemens Ag | Verfahren für eine Röntgeneinrichtung |
| DE102005052368B4 (de) * | 2005-10-31 | 2015-07-30 | Bayer Pharma Aktiengesellschaft | Röntgensystem zur Erstellung diagnostischer Röntgendarstellungen unter Applikation von Kontrastmitteln |
| DE102006040935A1 (de) * | 2006-08-31 | 2008-03-20 | Siemens Ag | Vorrichtung und Verfahren zur Aufnahme von Projektionsbildern eines zu untersuchenden Objekts in unterschiedlichen Energiebereichen |
| CN101547648B (zh) * | 2006-12-04 | 2012-02-22 | 皇家飞利浦电子股份有限公司 | Ct成像系统 |
| JP5105589B2 (ja) * | 2007-07-11 | 2012-12-26 | 株式会社日立メディコ | Ｘ線ｃｔ装置 |
| JP5461547B2 (ja) * | 2008-07-07 | 2014-04-02 | コーニンクレッカ フィリップス エヌ ヴェ | Ｋ端イメージング |
| KR101529876B1 (ko) * | 2008-10-10 | 2015-06-19 | 삼성전자주식회사 | 영상 처리 장치 및 방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3974386A (en) * | 1974-07-12 | 1976-08-10 | Wisconsin Alumni Research Foundation | Differential X-ray method and apparatus |
| DE3517101C1 (de) * | 1985-05-11 | 1986-10-09 | Deutsches Elektronen-Synchrotron Desy, 2000 Hamburg | Vorrichtung zur digitalen Subtraktions-Angiographie im Energiesubstraktions-Modus |
| JPS6395033A (ja) * | 1986-10-09 | 1988-04-26 | 株式会社日立製作所 | 分光型放射線画像撮影装置 |
| JP2502555B2 (ja) * | 1987-01-09 | 1996-05-29 | 松下電器産業株式会社 | 放射線エネルギ−弁別方法 |
| US5049746A (en) * | 1989-10-19 | 1991-09-17 | Fuji Photo Film Co., Ltd. | Method and apparatus for displaying energy subtraction images |
| JPH04200536A (ja) * | 1990-11-30 | 1992-07-21 | Hitachi Ltd | 分光型ｘ線画像撮影装置 |
| JPH05346500A (ja) * | 1992-06-16 | 1993-12-27 | Sumitomo Electric Ind Ltd | シンクロトロン放射光の波長切換装置 |
| US5434417A (en) * | 1993-11-05 | 1995-07-18 | The Regents Of The University Of California | High resolution energy-sensitive digital X-ray |
| DE10033497B4 (de) * | 2000-07-10 | 2006-09-07 | Martin-Luther-Universität Halle-Wittenberg | Röntgenkontrastverfahren zur Erzeugung eines elementselektiven Röntgenkontrastes durch digitale Absorptionskanten-Subtraktion von zwei Kontrastbildern |
| US6393097B1 (en) * | 2000-12-22 | 2002-05-21 | Ge Medical Systems Global Technology Company, Llc | Digital detector method for dual energy imaging |
| JP2002195961A (ja) * | 2000-12-25 | 2002-07-10 | Shimadzu Corp | Ｘ線撮像装置 |
| DE10118792B4 (de) * | 2001-04-05 | 2005-12-22 | Schering Ag | Anordnung zur Aufnahme von Projektionsmammogrammen und Verwendung der Anordnung für die Projektionsmammographie |
| US6816572B2 (en) * | 2002-03-08 | 2004-11-09 | Ge Medical Systems Global Technology Co., Llc | Method, system and computer product for processing dual energy images |
-
2003
- 2003-10-10 DE DE2003147961 patent/DE10347961A1/de not_active Ceased
-
2004
- 2004-10-07 JP JP2006530148A patent/JP2007508040A/ja active Pending
- 2004-10-07 EP EP04790320A patent/EP1673012A1/de not_active Withdrawn
- 2004-10-07 WO PCT/EP2004/011436 patent/WO2005034755A1/de active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2449729C2 (ru) | Рентгеновская установка для формирования изображения исследуемого объекта и ее применение | |
| US7672431B2 (en) | X-ray arrangement and x-ray contrast process for imaging an object under examination that contains at least one radiopaque element as well as use of the x-ray arrangement | |
| US20070025514A1 (en) | X-ray arrangement for graphic display of an object under examination and use of the x-ray arrangement | |
| US7869569B2 (en) | System for quantitative radiographic imaging | |
| US7330531B1 (en) | System for quantitative radiographic imaging | |
| US8000434B2 (en) | Energy spectrum reconstruction | |
| Haus et al. | Screen-film and digital mammography: image quality and radiation dose considerations | |
| US6714621B2 (en) | Method and apparatus for radiological examination by injection of a contrast medium | |
| Cowen | Digital x-ray imaging | |
| JP2007508040A5 (ru) | ||
| JP2007508040A (ja) | Ｘ線不透過性要素を含む少なくとも１つの被検体での画像形成用のｘ線装置及びｘ線コントラスト方法並びにｘ線装置の使用 | |
| EP1902677A1 (en) | Digital radiation image photography system | |
| Reilly | X‐Ray, CT, and Mammography Technology | |
| Tabakov et al. | Introduction to Diagnostic Radiology (X-Ray and Computed Tomography Imaging) | |
| Azhari et al. | X-Ray Imaging and Computed Tomography | |
| Jabri et al. | Management of pediatric radiation dose using GE’s Revolution digital radiography systems | |
| Treb | Development of a Photon Counting C-Arm Prototype System for Image-Guided Interventions | |
| Shuaib et al. | Examination Two: Questions | |
| Rothenberg | Optimization and Dose Reduction in Mammographic Imaging | |
| Tanaka et al. | Computed Radiography | |
| Luhta | John Yorkston | |
| Yang et al. | X-Ray Projection | |
| Dendy et al. | Special radiographic techniques | |
| Bronzino | X-Ray | |
| Rigon | Clinical Mammography With Synchrotron Radiation And The New Digital Development |